81.6 USD
-0.38 (-0.46%)
81.6 USD
0 (0%)
Taking everything into account, MIRM scores 4 out of 10 in our fundamental rating. MIRM was compared to 530 industry peers in the Biotechnology industry. While MIRM seems to be doing ok healthwise, there are quite some concerns on its profitability. MIRM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
MIRM had negative earnings in the past year.
In the past year MIRM had a positive cash flow from operations.
In the past 5 years MIRM always reported negative net income.
In the past 5 years MIRM reported 4 times negative operating cash flow.
1.2 Ratios
MIRM's Return On Assets of -5.30% is amongst the best of the industry. MIRM outperforms 86.04% of its industry peers.
With an excellent Return On Equity value of -14.26%, MIRM belongs to the best of the industry, outperforming 86.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROIC | N/A |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 79.92%, MIRM belongs to the best of the industry, outperforming 85.09% of the companies in the same industry.
MIRM's Gross Margin has declined in the last couple of years.
MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MIRM has more shares outstanding
Compared to 5 years ago, MIRM has more shares outstanding
The debt/assets ratio for MIRM has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.94 indicates that MIRM is not in any danger for bankruptcy at the moment.
The Altman-Z score of MIRM (4.94) is better than 72.26% of its industry peers.
MIRM has a debt to FCF ratio of 6.97. This is a slightly negative value and a sign of low solvency as MIRM would need 6.97 years to pay back of all of its debts.
MIRM's Debt to FCF ratio of 6.97 is amongst the best of the industry. MIRM outperforms 91.32% of its industry peers.
MIRM has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.06, MIRM is not doing good in the industry: 75.09% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Altman-Z | 4.94 |
ROIC/WACCN/A
WACC8.43%
2.3 Liquidity
A Current Ratio of 3.31 indicates that MIRM has no problem at all paying its short term obligations.
With a Current ratio value of 3.31, MIRM is not doing good in the industry: 60.38% of the companies in the same industry are doing better.
A Quick Ratio of 3.16 indicates that MIRM has no problem at all paying its short term obligations.
MIRM has a Quick ratio of 3.16. This is comparable to the rest of the industry: MIRM outperforms 40.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 57.43% over the past year.
Looking at the last year, MIRM shows a very strong growth in Revenue. The Revenue has grown by 53.66%.
The Revenue has been growing by 160.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
3.2 Future
MIRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.65% yearly.
The Revenue is expected to grow by 24.49% on average over the next years. This is a very strong growth
EPS Next Y78.72%
EPS Next 2Y38.47%
EPS Next 3Y33.4%
EPS Next 5Y31.65%
Revenue Next Year51.86%
Revenue Next 2Y34.95%
Revenue Next 3Y29.66%
Revenue Next 5Y24.49%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
MIRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
91.89% of the companies in the same industry are more expensive than MIRM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 94.43 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MIRM's earnings are expected to grow with 33.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.47%
EPS Next 3Y33.4%
5. Dividend
5.1 Amount
MIRM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
81.6
-0.38 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.71%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change0.26%
Market Cap4.19B
Revenue(TTM)471.79M
Net Income(TTM)-41.63M
Analysts86.25
Price Target104.35 (27.88%)
Short Float %16.95%
Short Ratio11.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.86%
Min EPS beat(2)63.96%
Max EPS beat(2)129.77%
EPS beat(4)3
Avg EPS beat(4)26.25%
Min EPS beat(4)-99.42%
Max EPS beat(4)129.77%
EPS beat(8)4
Avg EPS beat(8)-5.65%
EPS beat(12)7
Avg EPS beat(12)-12.67%
EPS beat(16)10
Avg EPS beat(16)-42.14%
Revenue beat(2)2
Avg Revenue beat(2)8.03%
Min Revenue beat(2)0.25%
Max Revenue beat(2)15.82%
Revenue beat(4)4
Avg Revenue beat(4)7.03%
Min Revenue beat(4)0.25%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)4.34%
Revenue beat(12)11
Avg Revenue beat(12)8.01%
Revenue beat(16)13
Avg Revenue beat(16)3.12%
PT rev (1m)16.25%
PT rev (3m)28.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)64.91%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)45.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.89 | ||
| P/FCF | 94.43 | ||
| P/OCF | 93.69 | ||
| P/B | 14.36 | ||
| P/tB | 69.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)0.86
FCFY1.06%
OCF(TTM)0.87
OCFY1.07%
SpS9.18
BVpS5.68
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% | ||
| FCFM | 9.41% |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.46% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z | 4.94 |
F-Score6
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y78.72%
EPS Next 2Y38.47%
EPS Next 3Y33.4%
EPS Next 5Y31.65%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
Revenue Next Year51.86%
Revenue Next 2Y34.95%
Revenue Next 3Y29.66%
Revenue Next 5Y24.49%
EBIT growth 1Y56.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.22%
EBIT Next 3Y33.68%
EBIT Next 5YN/A
FCF growth 1Y142.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y150.52%
OCF growth 3YN/A
OCF growth 5YN/A
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What is the fundamental rating for MIRM stock?
ChartMill assigns a fundamental rating of 4 / 10 to MIRM.
What is the valuation status for MIRM stock?
ChartMill assigns a valuation rating of 2 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.
Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for MIRM stock?
The Earnings per Share (EPS) of MIRUM PHARMACEUTICALS INC (MIRM) is expected to grow by 78.72% in the next year.